These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 38922160)

  • 1. Update on Non-Interchangeability of Botulinum Neurotoxin Products.
    Brin MF; Nelson M; Ashourian N; Brideau-Andersen A; Maltman J
    Toxins (Basel); 2024 Jun; 16(6):. PubMed ID: 38922160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response.
    Dolimbek BZ; Jankovic J; Atassi MZ
    Immunol Invest; 2002; 31(3-4):247-62. PubMed ID: 12472183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.
    Carr WW; Jain N; Sublett JW
    Adv Ther; 2021 Oct; 38(10):5046-5064. PubMed ID: 34515975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Application of Novel Test Methods to Evaluate the Potency of Botulinum Toxin: A Comparison Analysis among Widely Used Products in Korea.
    Hong JY; Kim JH; Jin JE; Shin SH; Park KY
    Toxins (Basel); 2021 Nov; 13(12):. PubMed ID: 34941671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
    Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum and Tetanus Neurotoxins.
    Dong M; Masuyer G; Stenmark P
    Annu Rev Biochem; 2019 Jun; 88():811-837. PubMed ID: 30388027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Structure and Classification of Botulinum Toxins.
    Dong M; Stenmark P
    Handb Exp Pharmacol; 2021; 263():11-33. PubMed ID: 31792680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future aspects of botulinum neurotoxins.
    Aoki KR
    J Neural Transm (Vienna); 2008; 115(4):567-73. PubMed ID: 17557128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
    Fredrick CM; Lin G; Johnson EA
    Appl Environ Microbiol; 2017 Jul; 83(13):. PubMed ID: 28455330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Expanding Therapeutic Utility of Botulinum Neurotoxins.
    Fonfria E; Maignel J; Lezmi S; Martin V; Splevins A; Shubber S; Kalinichev M; Foster K; Picaut P; Krupp J
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29783676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics.
    Behrensdorf-Nicol HA; Wild E; Bonifas U; Klimek J; Hanschmann KM; Krämer B; Kegel B
    Toxicol In Vitro; 2018 Dec; 53():80-88. PubMed ID: 30016653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
    Eleopra R; Tugnoli V; Quatrale R; Gastaldo E; Rossetto O; De Grandis D; Montecucco C
    Clin Neurophysiol; 2002 Aug; 113(8):1258-64. PubMed ID: 12140005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.
    Rasetti-Escargueil C; Palea S
    Toxins (Basel); 2024 Jun; 16(6):. PubMed ID: 38922155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of extracellular and intracellular potency of botulinum neurotoxins.
    Cai F; Adrion CB; Keller JE
    Infect Immun; 2006 Oct; 74(10):5617-24. PubMed ID: 16988237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.
    Tehran DA; Pirazzini M
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29748471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
    Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
    Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.